Our proprietary antibody humanisation technique and expertise help us deliver our charitable object of assisting the progress of scientific discoveries into therapeutic treatments.
We humanised the antibody now known as pembrolizumab (marketed as Keytruda®) for Organon in 2006, an essential step in the success of the therapeutic.
Keytruda was the first to market of a new generation of PD-1 therapies that block the biological pathways cancers use to disguise themselves from the immune system. It acts by making the cancer cell ‘visible’ to the immune system and thus the cell can be destroyed by the body’s natural defence mechanisms.
Our scientists played a significant early-stage role in bringing this new cancer treatment to patients. It represents an important milestone in the treatment of highly invasive tumours such as advanced melanoma.
To read more about how immunotherapy works read this blog by Michael Dalrymple, then Director of Business Development.
Read our Director of Drug Discovery, Justin Bryans’ article Immunotherapy drugs could herald new era in cancer treatment.All Case Studies